anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The occurrence of pulmonary visceral subpleural hematoma during care of post-cardiopulmonary resuscitation including chest compressions and anticoagulant and antiplatelet therapies is extremely rare. Also, there are few reports of treatment of visceral subpleural hematoma, most of which are treated by lung resection. Here we describe a rare case that pulmonary visceral subpleural hematoma arose during post-cardiopulmonary resuscitation care and was treated by hematoma evacuation.
CASE PRESENTATION: A 58-year-old male with no smoking history and, past medical histories of rheumatoid arthritis, chronic atrial fibrillation, hypertension, diabetes, and dyslipidemia developed ventricular fibrillation due to myocardial infarction and fainted. He received bystander cardiopulmonary resuscitation and defibrillation by the ambulance crew and had return of spontaneous circulation. After transfer to our hospital, the patient underwent percutaneous catheter intervention and stenting with a diagnosis of myocardial infarction, followed by anticoagulant and antiplatelet therapies. On the 8th hospital day, chest radiography suggested right lower lobe pneumonia, and subsequent chest computed tomography revealed pulmonary hematoma in the visceral subpleural area from S6 to S10. Since no improvement was observed in hypoxemia, treatment was considered necessary. First, an attempt at computed tomography-guided drainage of hematoma was made, but insertion of the Pig-tail catheter was difficult due to hardness of the hematoma. Next, evacuation of hematoma was performed on the 13th hospital day. The hematoma was located in the visceral subpleural area and was removed by incising the pleura. TachoSil Tissue Sealing sheet and Polyglycoal acid sheet were applied to the sites of air leakage and oozing after hematoma evacuation. No re-bleeding or air leakage was observed after the treatment, and the patient was discharged on the 26th hospital day after an uneventful course.
CONCLUSIONS: Pulmonary visceral subpleural hematoma may occur during post-cardiopulmonary resuscitation care, including chest compressions and anticoagulant and antiplatelet therapies. In our case, CT-guided puncture and drainage was difficult and surgical treatment by incision of the visceral pleura and hematoma evacuation alone was done successfully.
PURPOSE: Metabolic bariatric surgery (MBS) became integral to managing severe obesity. Understanding surgical risks associated with MBS is crucial. Different scores, such as the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP), aid in patient selection and outcome prediction. This study aims to evaluate machine learning (ML) models performance in predicting 30-day post-operative complications and compare them with the MBSAQIP risk score.
MATERIALS AND METHODS: We retrospectively evaluated 424 consecutive patients (2006-2020) who underwent MBS, analyzing 30-day surgical complications according to Clavien-Dindo Classification. ML models, including logistic regression, support vector machine, random forest, k-nearest neighbors, multi-layer perceptron, and extreme gradient boosting, were analyzed and compared to MBSAQIP risk score. Performance was measured by area under receiver operating characteristic curve (AUROC) analysis.
RESULTS: Random forest showed the highest AUROC in the training (AUROC = 0.94) and the validation set (AUROC = 0.88). ML algorithms, particularly random forest, outperformed MBSAQIP in predicting negative 30-day outcomes in both the training and validation sets (AUROC = 0.64, DeLong's Test p < 0.001). The five features that were more relevant for the prediction of the random forest model were serum alkaline phosphatase, platelet count, triglycerides, glycated hemoglobin, and albumin.
CONCLUSION: We developed several ML model that identifies patients at risk for 30-day complications after MBS. Among these, random forest is the most performing one and outperforms the already established MBSAQIP score. This model could increase the identification of high-risk patients before MBS.
More than one million Americans suffer an extremity fracture (broken bone in the arm, leg, or pelvis) that requires surgery each year. Approximately 5% (or 50,000) of surgical fracture patients develop a surgical site infection (SSI), which is twice the rate among most surgical patients and nearly five times the rate among patients undergoing elective orthopaedic surgeries (e.g. joint replacement). Patients who develop a SSI after their fracture fixation surgery experience a long and difficult treatment pathway. Researchers have identified that when a fracture patient experiences a SSI, they typically undergo at least two additional surgeries to control the infection, spend a median of 14 additional days in the hospital, and have significantly lower health related quality of life (HRQL). Similarly, results from the recently completed Fluid Lavage of Open Wounds (FLOW) trial confirmed that patients who had a SSI, or another complication, that required an additional surgery reported significantly lower physical and mental HRQL in the 12 months following their fracture compared to patients who did not experience a SSI. In the most severe cases, when a SSI cannot be controlled, a limb amputation becomes necessary.

Open fractures, closed lower extremity fractures, and pelvic fractures represent some of the most severe musculoskeletal injuries. Due to their high-energy mechanisms, these fractures are often accompanied by soft-tissue injuries that contribute to unacceptably poor outcomes. The FLOW trial of 2,447 open fracture patients reported a 13.2% incidence of open fracture-related reoperations; Closed fractures of the lower extremity are also at high risk of complications, particularly when compared to closed upper extremity fractures. For example, the rate of SSI in closed tibial plateau and plafond fractures range from 5.6 - 11.9%, although some cohort studies have reported infection rates as high as 25.0%. This is contrast with SSI rates of \<5% for common upper extremity fractures like humeral shaft, forearm, or distal radius fractures. This is further illustrated in a series of 214 deep orthopaedic fracture infections, in which 58% occurred in the tibia and ankle, and only 10% occurred anywhere in the upper extremity. Finally, pelvic fractures are associated with some of the most challenging SSIs to treat among closed fractures because of their propensity to gram negative organisms and limitations in reconstruction options post-infection. Ultimately, infectious complications in these fracture populations lead to prolonged morbidity, loss of function, and potential limb loss.
BACKGROUND: While individual risk factors, including chronic corticosteroid use, alcohol abuse, and smoking, are implicated in osteonecrosis of the femoral head (ONFH), the degree to which multiple risk factors increase risk is unknown. This study aimed to: (1) identify the demographic characteristics of patients who have ONFH; (2) quantify the effects of individual risk factors on ONFH development; (3) quantify the effects of combined risk factors on ONFH development; and (4) determine the prognostic implications of combined risk factors on ONFH development.
METHODS: This was a retrospective cohort study. A national insurance database was used to study a population of 2,612,383 adult patients who had a 10-year follow-up period. There were 10,233 patients identified who had a diagnosis of ONFH. We identified patients who had chronic corticosteroid use, tobacco use, and/or alcohol abuse and assessed the risk of developing ONFH over a 10-year period. Patients who had individual and multiple risk factors were grouped for comparison, and Chi-square analyses were performed.
RESULTS: Higher proportions of patients who had each individual risk factor developed ONFH compared to proportions of patients who did not have risk factors. Patients who had combined risk factors were at greater risk of developing ONFH compared to patients who had no risk factors and those who had single risk factors. Combined risk factors demonstrated multiplicative effects on the development of ONFH: tobacco-alcohol risk ratio (RR) 5.25, corticosteroid-alcohol RR 10.20, tobacco-corticosteroid RR 8.69, and corticosteroid-tobacco-alcohol RR 12.54. Patients who had combined risk factors developed ONFH at younger ages than those who had single risk factors. Kaplan-Meier curve analyses demonstrated worse 10-year hip survival in the setting of combined risk factors.
CONCLUSIONS: Combined risk factors have a multiplicative effect on the risk of developing of atraumatic ONFH. Orthopaedic surgeons may care for at-risk individuals through modulation of risk factors.
LEVEL OF EVIDENCE: Retrospective Cohort Study, Level III.
PURPOSE:To provide picture data managing method and device capable of easily recording an observed result of a past radiation picture and knowing it without requiring the search of a chart at the time of observing the past radiation picture. CONSTITUTION:Information for accessing required picture data 10 and storing the data 10 in a memory 7 is inputted from an input means 8 to a CPU 6 and the data 10 stored in an optical disk 3 are accessed and stored in the memory 7. On the other hand, reserved word information 11 stored in the disk 3 is also read out and stored in the memory 7 by a reserved word displaying means 5. Information for displaying a picture is inputted from the means 8 and a radiation picture is reproduced as a visible image. Then information for displaying reserved words is inputted from the means 8 to the CPU 6 and the reserved words are displayed on a reproducing means 4. When an observer selects a reserved word corresponding to an observed result out of plural reserved words, the reserved word information is added to the picture data 10 and stored in the disk 3 again.
Pulmonary injury is one of the key restricting factors for the therapy of malignancies with chemotherapy or following radiotherapy for chest cancers. The lung is a sensitive organ to some severely toxic antitumor drugs, consisting of bleomycin and alkylating agents. Furthermore, treatment with radiotherapy may drive acute and late adverse impacts on the lung. The major consequences of radiotherapy and chemotherapy in the lung are pneumonitis and fibrosis. Pneumonitis may arise some months to a few years behind cancer therapy. However, fibrosis is a long-term effect that appears years after chemo/or radiotherapy. Several mechanisms such as oxidative stress and severe immune reactions are implicated in the progression of pulmonary fibrosis. Epithelial-mesenchymal transition (EMT) is offered as a pivotal mechanism for lung fibrosis behind chemotherapy and radiotherapy. It seems that pulmonary fibrosis is the main consequence of EMT after chemo/radiotherapy. Several biological processes, consisting of the liberation of pro-inflammatory and pro-fibrosis molecules, oxidative stress, upregulation of nuclear factor of κB and Akt, epigenetic changes, and some others, may participate in EMT and pulmonary fibrosis behind cancer therapy. In this review, we aim to discuss how chemotherapy or radiotherapy may promote EMT and lung fibrosis. Furthermore, we review potential targets and effective agents to suppress EMT and lung fibrosis after cancer therapy.
PCT No. PCT/US89/00270 Sec. 371 Date Aug. 30, 1990 Sec. 102(e) Date Aug. 30, 1990 PCT Filed Jan. 23, 1989.A biologically active CSF-1 protein is selectively conjugated via certain amino acid residues or carbohydrate moieties to a water-soluble polymer selected from polyethylene glycol or polypropylene glycol homopolymers, polyoxyethylated polyols, or polyvinyl alcohol. The resulting conjugated CSF-1 is biologically active and has increased circulating half-life in mammals, compared to that of the unconjugated protein. The conjugated CSF-1 may be used to stimulate the immune response or to provide more cells to be stimulated.
One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
The invention provides a traditional Chinese medicine for treating nasitis, which is characterized by being prepared by decocting 15g of magnolia flowers, 15g of honeysuckle, 10g of dandelion, 10g of Chinese violet, 10g of divaricate saposhnikwovia roots, 5g of cicada slough, 10g of baical skullcap roots, 8g of bark of tree peony, 8g of chrysanthemum, 10g of dittany bark, 8g of rhizoma typhonii and 8g of cassia twig with water to obtain 500ml of liquid medicine. The liquid medicine steam is used for fumigating the nose while the liquid medicine is hot. During fumigating, the patient inhales the medicine steam deeply into the nasal cavity. After the liquid medicine turns warm, the liquid medicine can be used for washing the nasal cavity. The liquid medicine can be used for fumigating and washing for three times every day, and nasitis can be cured in 3-5 consecutive days. The traditional Chinese medicine can be prepared at home, has no side effect and is safe to use.
1. Use docetaxel or a hydrate thereof as an active ingredient for manufacture a medicament for the treatment of hepatocellular carcinoma. 2. Use of claim 1, wherein the hydrate is the trihydrate. 3. Use of claim 1 or 2, wherein the medicament is for parenteral administration. 4. Use according to claim 3, which is suitable for intraperitoneal, subcutaneous, intravenous, intramuscular or intrasternal administration and contains from 38 to 42 mg/ml of active compound. 5. Use according to claim 3, wherein the medicament is suitable for administration by infusion and contains from 0.1 to 11 mg/ml of active compound.
The acne treatment method of the present invention includes applying to skin a composition including an effective amount of acne treatment medication selected from the group consisting of benzoyl peroxide and salicylic acid, an effective amount of a vasoconstrictor and an inert carrier. The acne treatment medication is therapeutic to acne conditions by acting as an antibacterial agent. The vasoconstrictor removes the redness normally associated with acne conditions as well as additional redness which may be caused by the benzoyl peroxide itself. The carrier is simply an inert flowing carrier to permit the application of the active ingredients to the skin. In preferred embodiments about 1 to 15% of the acne treatment medication based on the total weight of the composition is included. The preferred acne treatment medication is benzoyl peroxide and the preferred vasoconstrictor is tetrahydrozoline hydrochloride or a combination of tetrahydrozoline hydrochloride and zinc sulfate.
Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules 5 mg: Capsule with white opaque body and lime green cap (imprinted 5 mg on body and ELI-510 on cap with black ink). Capsules filled with orange pellets.

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules 10 mg: Capsule with blue body and blue cap (imprinted 10 mg on body and ELI-511 on cap with black ink). Capsule filled with orange pellets. 

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules 15 mg: Capsule with white opaque body and green cap (imprinted 15 mg on body and ELI-512 on cap with black ink). Capsule filled with orange pellets.

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules 20 mg: Capsule with white opaque body and light pink cap (imprinted 20 mg on body and ELI-513 on cap with black ink). Capsule filled with orange pellets. 

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules 25 mg: Capsule with pink body and pink cap (imprinted 25 mg on body and ELI-514 on cap with black ink). Capsule filled with orange pellets.

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules 30 mg: Capsule with white opaque body and dark pink cap (imprinted 30 mg on body and ELI-515 on cap with black ink). Capsule filled with orange pellets.
The present invention relates to a Chinese mecicine for treating coronary disease and a preparation method thereof. The medicine is prepared from the following fourteen raw materials of ginseng, milkvetch root, rehmanniae, ophiopogon root, etc. as active ingredients. The Affiliated Hospital of the Changchun Traditional Chinese Medical College, the First Affiliated Hospital of the Heilongjiang Traditional Chinese Medicine university, the second Affiliated Hospital of the Heilongjiang Traditional Chinese Medicine university and the Heilongjiang Traditional Chinese Medicine Research Institute clinically observe 400 cases of patients with coronary disease, wherein 300 cases are treated by the medicine of the present invention; the result shows that the total effectual rate of the present invention to angina pectoris is 46.33%, the total effective rate is 89.14%, the total effectual rate of the electrocardiogram is 22.04%, and the total effective rate is 61.02%. clinical observation shows that the present invention can effectively relieve or eliminate simultaneous symptoms of angina pectoris, oppression in chest, shortness of breath, palpitation, vertigo, etc. simultaneously, the present invention has an obvious improvement function on the electrocardiograph. The present invention does not have the toxic or side effects of damaging liver function, renal function, etc., is a truly effective medicine for treating coronary disease and has excellent popularization and application value.
Bone marrow edema (BME) is a frequent MRI finding in patients with knee pain. According to the etiology, BME of the knee can be classified into three main categories: ischemic, mechanic, and reactive. The diagnosis may be difficult, because of the specificity of symptoms and the poor radiographic findings. MRI is the gold standard, showing an area of altered signal of the bone with an high signal intensity on fat-suppressed, T2 weighted images, usually in combination with an intermediate or low signal intensity on T1 weighted images. Bone marrow edema tends to be self-limiting and, in most cases, resolves without any consequences in a varying amount of time. However, since it may evolve to complete joint destruction, early diagnosis and correct treatment are crucial to prevent the articular degeneration. Conservative therapy is the first step, with no weight-bearing for 3 to 6 weeks on the affected side, in combination with the administration of anti-inflammatory drugs or painkillers to manage symptoms. In non-responding forms and more advanced stages, minimally invasive preservative surgery can provide significant results, with subchondroplasty and core decompression being the two main procedures available. Knee arthroplasty, both total (TKA) or unicompartmental (UKA), is the only effective option when the degradation of cartilage is diffuse and in patients with subchondral bone collapse.
This is a randomized (individuals will be assigned by chance to study treatments), open-label (individuals will know the identity of study treatments), 4-period, 5-treatment crossover study in order to evaluate the relative bioavailability of 4 new formulations of abiraterone acetate compared to the current commercial formulation. Approximately 32 healthy adult males will participate. The total study length is up to 68 days. This study will consist of a screening phase followed by an open-label treatment phase consisting of 4 single-dose treatment periods separated by a washout period of at least 7 days between dosing. Individuals will be randomly assigned to 1 of 8 treatment sequences. A single dose of 1000 mg abiraterone acetate will be given in each treatment period under fasted conditions. Participants will be confined to the study center from Day -1 of each treatment period until completion of the 96-hour blood sample collection on Day 5 of each treatment period. A follow-up visit will occur between 5 to 7 days after the last study procedure. Serial pharmacokinetic (study of what the body does to a drug) samples will be collected during the open-label treatment phase as detailed in the protocol. Safety will be monitored throughout the study.
No intervention will be made to women in the control group. However, data collection forms will be applied 3 times in total, before the intervention, in the second and the fourth week.
Participants self-administered SAGE-217 50 mg capsules, once daily at approximately 8 PM with fat-containing food for 14 days. Participants who could not tolerate 50 mg received 40 mg for the remainder of the treatment period as per discretion of investigator.
There is growing evidence supporting clinically important associations between age at neutering in bitches and subsequent urinary incontinence (UI), although much of this evidence to date is considered weak. Target trial emulation is an innovative approach in causal inference that has gained substantial attention in recent years, aiming to simulate a hypothetical randomised controlled trial by leveraging observational data. Using anonymised veterinary clinical data from the VetCompass Programme, this study applied the target trial emulation framework to determine whether later-age neutering (≥ 7 to ≤ 18 months) causes decreased odds of early-onset UI (diagnosed < 8.5 years) compared to early-age neutering (3 to < 7 months). The study included bitches in the VetCompass database born from January 1, 2010, to December 31, 2012, and neutered between 3 and 18 months old. Bitches were retrospectively confirmed from the electronic health records as neutered early or later. The primary outcome was a diagnosis of early-onset UI. Informed from a directed acyclic graph, data on the following covariates were extracted: breed, insurance status, co-morbidities and veterinary group. Inverse probability of treatment weighting was used to adjust for confounding, with inverse probability of censoring weighting accounting for censored bitches. The emulated trial included 612 early-age neutered bitches and 888 later-age neutered bitches. A pooled logistic regression outcome model identified bitches neutered later at 0.80 times the odds (95% CI 0.54 to 0.97) of early-onset UI compared with bitches neutered early. The findings show that later-age neutering causes reduced odds of early-onset UI diagnosis compared with early-age neutering. Decision-making on the age of neutering should be carefully considered, with preference given to delaying neutering until after 7 months of age unless other major reasons justify earlier surgery. The study is one of the first to demonstrate successful application of the target trial framework to veterinary observational data.
The oligometastatic disease state is an increasingly recognized phenomenon in prostate cancer. Ga-68 PSMA PET/CT has high accuracy in the diagnosis metastases from prostate cancer. In this protocol, pretreatment Ga-68 PSMA PET/ CT shall be performed in all patients.

ADT is considered standard of care treatment for advanced prostate cancer. But hormonal therapy can have side effects that greatly trouble men and lead to castration-resistant prostate cancer (CRPC). Any effort to delay the start of hormonal therapy would be an advantage to the patient. Stereotactic body radiation therapy (SBRT) is highly focused radiation, given in a very dose intensive fashion and delivered in usually less than one week. SBRT has been shown to be very effective on bone or lymph nodes metastases. Therefore, we are studying the safety and feasibility of SBRT on patients with five or fewer prostate cancer bone or lymph nodes metastases to determine if we can stall the use of hormonal therapy and/or prevent other site metastases from developing elsewhere in the body.